EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Activation of epigenetic reprogramming via crotonylation overcomes resistance to EGFR-TKI therapy in lung cancer

Sihong Chen, Mengyan Zhong, Xiaoyuan Wang, Youwei Su, Yingxi Zhao, Simeng Wang, Shougeng Liu, Yongshan Zhao iD, Yang Zhang, Xinyu Fan, Zongang Liu, Lina Jia und 6 weitere

Proceedings of the National Academy of Sciences · 2025

DOI: 10.1073/pnas.2509255122 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, 2025. Verfasst von Sihong Chen und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, School of Life Science and Biopharmaceutics, Shenyang Pharmaceutical University, Shenyang 110016, People's Republic of Ch…. Hauptthemen laut MEDLINE: Lung Neoplasms, Drug Resistance, Neoplasm, Epigenesis, Genetic, Protein Kinase Inhibitors. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: MOST | National Natural Science Foundation of China (NSFC), Liaoning Provonvial Department of Education.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Posttranslational modifications (PTMs) on histones play critical roles in cellular processes, including gene expression and tumorigenesis. However, the regulatory mechanisms and functional consequences of newly identified lysine acylation modifications in cancer therapy remain to be elucidated. Here, we established diverse preclinical tumor models resistant to epithelial growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) and focused on histone lysine crotonylation (Kcr), as it exhibited more pronounced alterations compared to other acylations. Next, we identified acyl-CoA synthetase short-chain family member 2 as a key regulator responsible for the resistance-associated decrease in crotonylation levels. Furthermore, integrated crotonylomic, transcriptomic, and epigenomic profiling, supplemented by gene manipulation studies, revealed that EGFR-TKI resistance resulted from transcriptional suppression of HNF1A and activation of the PI3K/AKT signaling pathway, which were regulated by reduced histone H3 lysine 56 crotonylation. Importantly, through pharmacological screening, we identified a histone decrotonylase inhibitor that enhanced EGFR-TKI sensitivity by activating epigenetic reprogramming through the selective upregulation of histone Kcr levels across multiple models in vitro and in vivo. Collectively, our findings uncover a previously unrecognized epigenetic mechanism driven by crotonylation that contributes to EGFR-TKI resistance, highlighting the potential of modulating crotonylation as a novel therapeutic strategy to enhance the efficacy of EGFR-TKIs in lung cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lung NeoplasmsDrug Resistance, NeoplasmEpigenesis, GeneticProtein Kinase InhibitorsHumansErbB ReceptorsAnimalsMiceHistonesCell Line, TumorProtein Processing, Post-TranslationalSignal TransductionGene Expression Regulation, NeoplasticLysineAcylationMice, NudeXenograft Model Antitumor Assays

Stichwörter der Autor:innen

EGFR-TKI resistanceepigeneticshistone modificationslysine crotonylationnon–small cell lung cancer

Substanzen

ErbB ReceptorsProtein Kinase InhibitorsHistonesEGFR protein, humanLysine

Autor:innen und Institutionen

  • Department of Pharmacology, School of Life Science and Biopharmaceutics, Shenyang Pharmaceutical University, Shenyang 110016, People's Republic of China.
  • Division of Drug Screening and Biology Evaluation, Benxi Institute of Pharmaceutical Research, Shenyang Pharmaceutical University, Benxi 117004, People's Republic of China.
  • Key Laboratory of Structure-Based Drug Design and Discovery of Ministry of Education, Department of Medicinal Chemistry, School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, Shenyang 110016, People'…
  • Department of Biochemistry and Molecular Biology, School of Life Science and Biopharmaceutics, Shenyang Pharmaceutical University, Shenyang 110016, People's Republic of China.
  • Department of Pharmacy, Shengjing Hospital of China Medical University, Shenyang 110004, People's Republic of China.
  • Department of Thoracic Surgery, Shengjing Hospital of China Medical University, Shenyang 110004, People's Republic of China.

ORCID-Profile: Yongshan Zhao, Lihui Wang

Förderung

  • MOST | National Natural Science Foundation of China (NSFC)
  • Liaoning Provonvial Department of Education

Zitieren

APA

Chen, S., Zhong, M., Wang, X., Su, Y., Zhao, Y., Wang, S., Liu, S., Zhao, Y., Zhang, Y., Fan, X., Liu, Z., Jia, L., Bao, X., Cui, W., Yang, J., Wu, C., Chen, G., & Wang, L. (2025). Activation of epigenetic reprogramming via crotonylation overcomes resistance to EGFR-TKI therapy in lung cancer. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.2509255122

Vancouver

Chen S, Zhong M, Wang X, Su Y, Zhao Y, Wang S, et al. Activation of epigenetic reprogramming via crotonylation overcomes resistance to EGFR-TKI therapy in lung cancer. Proceedings of the National Academy of Sciences. 2025. doi:10.1073/pnas.2509255122

BibTeX
@article{Chen2025,
  author = {Chen, Sihong and Zhong, Mengyan and Wang, Xiaoyuan and Su, Youwei and Zhao, Yingxi and Wang, Simeng and Liu, Shougeng and Zhao, Yongshan and Zhang, Yang and Fan, Xinyu and Liu, Zongang and Jia, Lina and Bao, Xuefei and Cui, Wei and Yang, Jingyu and Wu, Chunfu and Chen, Guoliang and Wang, Lihui},
  title = {Activation of epigenetic reprogramming via crotonylation overcomes resistance to EGFR-TKI therapy in lung cancer},
  journal = {Proceedings of the National Academy of Sciences},
  year = {2025},
  doi = {10.1073/pnas.2509255122}
}
Kostenlos starten →